Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced a poster presentation of preclinical data for EDP-721, a novel oral HBV RNA destabilizer, at the EASL International Liver Congress 2021, scheduled for June 23-26, 2021. The presentation, titled 'Discovery and characterization of EDP-721,' will be led by Michael Vaine, Ph.D., and focuses on the potential of EDP-721 for an all-oral functional cure of hepatitis B virus. The company is also engaged in developing treatments for respiratory syncytial virus and other liver diseases.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced on May 18, 2021, that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at 1:20 p.m. ET. Investors can access a live webcast of the event on Enanta’s website, with a replay available for approximately 90 days afterward.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases. Their clinical candidates target RSV, HBV, and NASH, with funding primarily from royalties on HCV products developed in collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced promising results from its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients. The drug demonstrated safety and tolerability while achieving a mean reduction of HBV RNA of 1 log after 28 days, compared to 0.3 log in the placebo group. The study included 24 patients treated with nucleoside reverse transcriptase inhibitors. EDP-514 showed favorable pharmacokinetics for once-daily dosing, paving the way for combination therapies aimed at achieving functional cures for chronic HBV infection.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2021 results, with total revenue of $20.1 million, down from $27.6 million year-over-year, impacted by the pandemic's effects on HCV sales. R&D expenses rose to $41.5 million from $32.6 million, while G&A expenses increased to $8.3 million. The net loss widened to $22.0 million, or $1.09 per diluted share, compared to $6.0 million, or $0.30 per share, in Q2 2020. Enanta remains well-capitalized with $400.4 million in cash, supporting its ongoing clinical programs in HBV, RSV, and NASH.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced it plans to report its financial results for the fiscal second quarter ending March 31, 2021, after U.S. market close on May 6, 2021. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on the company's R&D pipeline, focusing on treatments for viral infections and liver diseases. Key areas of development include candidates for respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta's activities are primarily funded through royalties from HCV products developed with AbbVie.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly will present at three virtual investor conferences. Key presentations include:
- H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021
- 33rd Annual Roth Conference on March 15, 2021, discussing COVID-19 therapies
- Oppenheimer & Co. Healthcare Conference on March 16, 2021
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., its CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 8:40 am ET. The presentation will be accessible via live webcast on Enanta's website, with a replay available for 90 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates for respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis. Their research is funded by royalties from hepatitis C products developed with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q1 2021 results, highlighting a revenue decline to $31.7 million from $52.6 million due to lower HCV sales. R&D expenses increased to $36.7 million, and net loss expanded to $8.3 million, or $0.41 per share. Key pipeline advancements include ongoing Phase 1b trials for HBV drugs EDP-514 and EDP-721, and the Phase 2b study for RSV drug EDP-938. The company expects preliminary data from its HBV trials in Q2 2021 and aims to identify two clinical candidates in respiratory virology this year.
Enanta Pharmaceuticals (NASDAQ:ENTA) will report its fiscal Q1 results on February 8, 2021, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on its R&D pipeline, targeting viral infections and liver diseases. Enanta’s research focuses on diseases like respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis, with funding derived from royalties from its collaboration with AbbVie for hepatitis C virus treatments.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced the appointment of Brendan Luu as Senior Vice President of Business Development, enhancing its leadership team. With over 20 years of experience in the pharmaceutical sector, Luu previously held significant roles at Merck KGaA, focusing on business development strategies. This transition comes as Enanta prepares for a catalyst-rich year, particularly in advancing its pipeline targeting viral infections and liver diseases, including promising candidates for RSV and hepatitis B.